GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seig
0
0
24/09/24
Dans
Amérique du Nord / États-Unis
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Montre plus
0 commentaires
sort Trier par
